AHU-377: High-Purity Neprilysin Inhibitor for Pharmaceutical Research & Development | NINGBO INNO PHARMCHEM CO.,LTD.

Discover AHU-377, a leading neprilysin inhibitor crucial for cardiovascular drug research. As a trusted manufacturer and supplier in China, we ensure high purity and reliable supply for your pharmaceutical development needs. Enquire today for competitive pricing and detailed specifications.

Get a Quote & Sample

Advantages of Sourcing AHU-377 from NINGBO INNO PHARMCHEM CO.,LTD.

Uncompromising Purity and Quality

Our AHU-377 is manufactured under stringent quality control, ensuring a purity of ≥98% (HPLC), vital for reproducible research outcomes. Partner with a trusted supplier for your pharmaceutical intermediate needs.

Global Supply Chain and Competitive Pricing

As a leading manufacturer in China, we offer competitive AHU-377 price points and a robust supply chain. We facilitate your purchase of this critical compound, ensuring timely delivery for your research and development programs.

Expertise in Pharmaceutical Intermediates

Leverage our deep expertise in fine chemicals and pharmaceutical intermediates. Our commitment to excellence makes NINGBO INNO PHARMCHEM CO.,LTD. your go-to source for high-quality research chemicals.

Key Applications of AHU-377 in Pharmaceutical R&D

Cardiovascular Drug Development

AHU-377 is a cornerstone in developing novel therapies for heart failure and hypertension, offering researchers a reliable tool to explore neprilysin inhibition pathways.

Pharmaceutical Intermediate Manufacturing

As a crucial intermediate, AHU-377 supports the synthesis of complex drug molecules, enabling manufacturers to produce advanced pharmaceuticals for global markets.

Biochemical Research Tools

Researchers globally utilize AHU-377 for its specific biological activity, studying enzyme kinetics and developing new therapeutic strategies for various physiological conditions.

Drug Discovery and Screening

Its well-defined inhibitory profile makes AHU-377 a valuable compound for drug screening and discovery programs aiming to target the renin-angiotensin-aldosterone system (RAAS) and natriuretic peptides.